TetraLogic halts study enrollment By: MarketMinute.com Stock News May 06, 2015 at 17:11 PM EDT TetraLogic Pharmaceuticals Corp. (Nasdaq: TLOG) temporarily halted enrollment in a chronic hepatitis B trial sending the stock price plummeting $1.38 to close at $2.40.